CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
stock NASDAQ

Credit to u/Mango-Livid:
Here's some information on why at about $0.50≈ $50m market capitalisation it's so undervalued. And why I feel it would be more fairly valued at around $300m-$500m at this stage.
It's worth noting a couple of other single-asset schizophrenia drug companies comparisons for anyone doing DD in the space, and why I believe people should be willing to buy.
1. ⁠LBRX (LB pharma) - currently with a market cap of $300m after their IPO in September 2025. Their drug is in P2 - they still have a P3 and 12 month safety study to do, and the efficacy and safety of LB's drug are objectively worse than Reviva's drug.
2. ⁠Karuna KRTX: Bought for $14b (Market cap of about $9b before buyout) by BMY in 2023 after the NDA was submitted. The drug KarXT, now known as Cobenfy has efficacy that's not far off, but not as good as, Reviva's. Their safety has a different profile, with a laundry list of undesirable side effects.
3. ⁠Cerevel CERE: Bought for $8.7b (Market cap of about $5b before buyout) by Abbvie in 2023 after just Phase 1 trials. The drug, emraclidine, failed phase 2.
A 14billion sale that means that Karuna's drug was apparently worth 280 times more than Reviva. 280. 10x sure. 20x...maybe. But more than 100x more? Is it going to sell 100x Reviva's once approved? I think not. KRTX and CERE had higher valuations because of a new mechanism of action. New mechanisms of action don't matter to prescribers unless they have better efficacy or better safety than anything else. Efficacy and safety are what gives a drug, and therefore a company value. And Reviva's Brilaroxazine kicks Cobenfy's ykw in both of those areas.
Don't worry about the stock price, worry about the market cap. Reviva should be worth $300m at least at this stage with this data. Even if they need extra funding, Reviva are soooo much further along than LBRX, with a better drug. It's a comfortable buy until the market cap hits $300m.
Yes there are challenges with Reviva in terms of funding the next trial if the FDA says it's required, and the patent life may be shorter compared to peers but even so. The valuation disparity is CRAZY.

Credit to u/Mango-Livid:
Here's some information on why at about $0.50≈ $50m market capitalisation it's so undervalued. And why I feel it would be more fairly valued at around $300m-$500m at this stage.
It's worth noting a couple of other single-asset schizophrenia drug companies comparisons for anyone doing DD in the space, and why I believe people should be willing to buy.
1. ⁠LBRX (LB pharma) - currently with a market cap of $300m after their IPO in September 2025. Their drug is in P2 - they still have a P3 and 12 month safety study to do, and the efficacy and safety of LB's drug are objectively worse than Reviva's drug.
2. ⁠Karuna KRTX: Bought for $14b (Market cap of about $9b before buyout) by BMY in 2023 after the NDA was submitted. The drug KarXT, now known as Cobenfy has efficacy that's not far off, but not as good as, Reviva's. Their safety has a different profile, with a laundry list of undesirable side effects.
3. ⁠Cerevel CERE: Bought for $8.7b (Market cap of about $5b before buyout) by Abbvie in 2023 after just Phase 1 trials. The drug, emraclidine, failed phase 2.
A 14billion sale that means that Karuna's drug was apparently worth 280 times more than Reviva. 280. 10x sure. 20x...maybe. But more than 100x more? Is it going to sell 100x Reviva's once approved? I think not. KRTX and CERE had higher valuations because of a new mechanism of action. New mechanisms of action don't matter to prescribers unless they have better efficacy or better safety than anything else. Efficacy and safety are what gives a drug, and therefore a company value. And Reviva's Brilaroxazine kicks Cobenfy's ykw in both of those areas.
Don't worry about the stock price, worry about the market cap. Reviva should be worth $300m at least at this stage with this data. Even if they need extra funding, Reviva are soooo much further along than LBRX, with a better drug. It's a comfortable buy until the market cap hits $300m.
Yes there are challenges with Reviva in terms of funding the next trial if the FDA says it's required, and the patent life may be shorter compared to peers but even so. The valuation disparity is CRAZY.